Cue Biopharma
74 hedge funds and large institutions have $185M invested in Cue Biopharma in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 6 closing their positions.
Holders
74
Holders Change
+11
Holders Change %
+17.46%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
18
Increased
23
Reduced
16
Closed
6
Calls
–
Puts
$443K
Net Calls
-$443K
Net Calls Change
-$443K
Top Buyers
| 1 |
NCM
1
Nantahala Capital Management
New Canaan,
Connecticut
|
$35.5M |
| 2 |
CA
2
Corriente Advisors
Fort Worth,
Texas
|
$11.6M |
| 3 |
PM
3
Prosight Management
Dallas,
Texas
|
$7.83M |
| 4 |
4
Goldman Sachs
New York
|
$2.22M |
| 5 |
GTC
5
Ghost Tree Capital
New York
|
$1.77M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
76
HSBC Holdings
London,
United Kingdom
| – | -$473K | -30,282 | Closed |
|
|
OAM
77
Oxford Asset Management
Oxford,
United Kingdom
| – | -$287K | -18,092 | Closed |
|
|
LI
78
Leap Investments
Chicago,
Illinois
| – | -$241K | -15,173 | Closed |
|
79
D.E. Shaw & Co
New York
| – | -$205K | -12,908 | Closed |
|
80
Marshall Wace
London,
United Kingdom
| – | -$2K | -100 | Closed |
|